Zkusit zdarma
Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc.

TRDA
Cena:
$ 6.56
+0.25 (3.96%)
Valuace
70
Růst
23
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

15:33 21-05-2026

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors ...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

17:25 19-05-2026

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest...

INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC

INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC

8:00 18-05-2026

ATLANTA, May 18, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Entrada Ther...

TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

21:54 17-05-2026

LOS ANGELES, May 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights lit...

TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

21:54 17-05-2026

LOS ANGELES, May 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights lit...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

22:30 14-05-2026

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors ...

Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript

Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript

12:20 11-05-2026

Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript...

Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

10:40 11-05-2026

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims o...

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile

2:09 09-05-2026

Entrada Therapeutics NASDAQ: TRDA said initial data from the first cohort of its phase I/II ELEVATE-...

Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

13:38 07-05-2026

Entrada Therapeutics, Inc. (NASDAQ:TRDA) stock is trading lower on Thursday as the stock reacts to n...

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates

9:56 07-05-2026

Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.95 per share versus the Zacks...

Entrada Therapeutics Reports First Quarter 2026 Financial Results

Entrada Therapeutics Reports First Quarter 2026 Financial Results

7:10 07-05-2026

-- Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing...

Entrada's Duchenne drug shown to improve muscle function in early trial

Entrada's Duchenne drug shown to improve muscle function in early trial

7:04 07-05-2026

Entrada Therapeutics said on Thursday its drug improved a key measure of muscle function in children...

Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?

Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?

10:16 05-05-2026

Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being highe...

Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week High on Analyst Upgrade

Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week High on Analyst Upgrade

1:44 07-04-2026

Entrada Therapeutics, Inc. (NASDAQ: TRDA - Get Free Report) reached a new 52-week high during mid-da...

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Rating of “Moderate Buy” from Analysts

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Rating of “Moderate Buy” from Analysts

4:46 07-03-2026

Entrada Therapeutics, Inc. (NASDAQ: TRDA - Get Free Report) has been given an average recommendation...

Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline

Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline

11:01 19-02-2026

Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a l...

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

7:00 17-02-2026

-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201  -- --...

Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit

Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit

2:03 17-02-2026

Entrada Therapeutics (NASDAQ: TRDA) used a presentation at Guggenheim's 2026 Emerging Outlook Biotec...

Entrada Therapeutics to Present at Upcoming Investor Conferences

Entrada Therapeutics to Present at Upcoming Investor Conferences

7:00 04-02-2026

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced ...

close

ENTRADA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

04-02-2026
BOSTON, FEB. 04, 2026 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED ...
Více zde

ENTRADA THERAPEUTICS HIGHLIGHTS PROGRESS ACROSS ITS PORTFOLIO OF RNA-BASED THERAPEUTICS FOR THE TREATMENT OF NEUROMUSCULAR AND OCULAR DISEASES

08-01-2026
-- COMPANY ON TRACK TO REPORT ELEVATE-44-201 DATA FROM THE FIRST COHORT IN Q2 2026 AND ELEVATE-45-20...
Více zde

ENTRADA THERAPEUTICS TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

17-12-2025
BOSTON, DEC. 17, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED ...
Více zde

ENTRADA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

04-12-2025
BOSTON, DEC. 04, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED ...
Více zde

ENTRADA THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

06-11-2025
-- COMPANY ON TRACK TO REPORT ELEVATE-44-201 DATA FROM FIRST PATIENT COHORT IN Q2 2026 -- -- FIRST P...
Více zde

ENTRADA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

28-10-2025
BOSTON, OCT. 28, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED ...
Více zde

ENTRADA THERAPEUTICS ANNOUNCES RECIPIENTS OF THIRD ANNUAL DREAMS GRANT PROGRAM

05-09-2025
-- THE 2025 DREAMS GRANT PROGRAM AWARDS $50,000 EACH TO TWO NON-PROFIT ORGANIZATIONS WORKING TO ADVA...
Více zde

ENTRADA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

02-09-2025
BOSTON, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED...
Více zde

ENTRADA THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

06-08-2025
-- FIRST PATIENT DOSED IN ELEVATE-44-201 WITH DATA FROM FIRST PATIENT COHORT ANTICIPATED IN H1 2026 ...
Více zde

ENTRADA THERAPEUTICS APPOINTS MAHA RADHAKRISHNAN, M.D., TO ITS BOARD OF DIRECTORS

03-06-2025
BOSTON, JUNE 03, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED ...
Více zde

ENTRADA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

02-06-2025
BOSTON, JUNE 02, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED ...
Více zde

ENTRADA THERAPEUTICS RECEIVES AUTHORIZATION IN THE EUROPEAN UNION TO INITIATE ELEVATE-45-201, A PHASE 1/2 MULTIPLE ASCENDING DOSE CLINICAL STUDY OF ENTR-601-45 IN PATIENTS LIVING WITH DUCHENNE MUSCULAR DYSTROPHY AMENABLE TO EXON 45 SKIPPING

28-05-2025
– COMPANY ON TRACK TO BEGIN ELEVATE-45-201 IN Q3 2025 – – FOLLOWS RECENTLY RECEIVED MEDICINES ...
Více zde

ENTRADA THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

08-05-2025
– RECEIVES REGULATORY AUTHORIZATION IN THE EU FOR ELEVATE-44-201, A PHASE 1/2 MAD CLINICAL STUDY O...
Více zde

ENTRADA THERAPEUTICS RECEIVES AUTHORIZATION IN THE UNITED KINGDOM TO INITIATE ELEVATE-45-201, A PHASE 1/2 MULTIPLE ASCENDING DOSE CLINICAL STUDY OF ENTR-601-45 IN PEOPLE LIVING WITH DUCHENNE MUSCULAR DYSTROPHY AMENABLE TO EXON 45 SKIPPING

24-03-2025
– COMPANY ON TRACK TO INITIATE ELEVATE-45-201 STUDY IN Q3 2025 – – ELEVATE-45 REGULATORY FILIN...
Více zde

ENTRADA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

27-02-2025
– RECEIVED FDA AUTHORIZATION TO INITIATE ELEVATE-44-102 IN THE U.S. – – RECEIVED MHRA AUTHORIZ...
Více zde

ENTRADA THERAPEUTICS ANNOUNCES FDA REMOVAL OF CLINICAL HOLD ON ENTR-601-44

24-02-2025
– RECEIVES FDA AUTHORIZATION TO INITIATE ELEVATE-44-102, A PHASE 1B MULTIPLE ASCENDING DOSE CLINIC...
Více zde

ENTRADA THERAPEUTICS RECEIVES AUTHORIZATION IN THE UNITED KINGDOM TO INITIATE ELEVATE-44-201, A PHASE 1/2 MULTIPLE ASCENDING DOSE CLINICAL STUDY OF ENTR-601-44 IN PATIENTS LIVING WITH DUCHENNE MUSCULAR DYSTROPHY

03-02-2025
– COMPANY ON TRACK TO INITIATE ELEVATE-44-201 IN Q2 2025 – – ENTR-601-44 REGULATORY FILINGS SU...
Více zde

AZENTA ANNOUNCES THE ELECTION OF DIPAL DOSHI TO ITS BOARD OF DIRECTORS

30-01-2025
BURLINGTON, MASS. , JAN. 30, 2025 /PRNEWSWIRE/ -- AZENTA, INC. (NASDAQ: AZTA) TODAY ANNOUNCED THAT D...
Více zde

ENTRADA THERAPEUTICS TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

18-12-2024
BOSTON, DEC. 18, 2024 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) IS A CLINICAL-ST...
Více zde

ENTRADA THERAPEUTICS PRESENTS NEW DATA SUPPORTING ITS EXPANDING DUCHENNE FRANCHISE AT THE 29TH ANNUAL CONGRESS OF THE WORLD MUSCLE SOCIETY

09-10-2024
– ADDITIONAL POSITIVE DATA FROM THE COMPANY'S COMPLETED PHASE 1 CLINICAL TRIAL EVALUATING ENTR-601...
Více zde

ENTRADA THERAPEUTICS PROMOTES NATARAJAN SETHURAMAN, PHD, TO PRESIDENT OF RESEARCH AND DEVELOPMENT

24-09-2024
BOSTON, SEPT. 24, 2024 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) IS A CLINICAL-S...
Více zde

ĀSHIBIO ANNOUNCES APPOINTMENT OF DIPAL DOSHI, CEO OF ENTRADA THERAPEUTICS, TO ITS BOARD OF DIRECTORS

17-09-2024
BRISBANE, CALIF.--(BUSINESS WIRE)--ĀSHIBIO, A PRIVATELY HELD, CLINICAL-STAGE BIOTECHNOLOGY COMPANY ...
Více zde

ENTRADA THERAPEUTICS ANNOUNCES RECIPIENTS OF SECOND ANNUAL DIVERSITY, REPRESENTATION, EQUITY AND ADVOCACY MATTERS (DREAMS) GRANT PROGRAM

06-09-2024
- SECOND ANNUAL DREAMS GRANT PROGRAM AWARDS $25,000 EACH TO THREE U.S.-BASED NON-PROFIT ORGANIZATION...
Více zde

ENTRADA THERAPEUTICS ANNOUNCES $100 MILLION REGISTERED DIRECT OFFERING

24-06-2024
– THE OFFERING WAS LED BY A U.S.-BASED HEALTHCARE FOCUSED INVESTOR, TWO GLOBAL MUTUAL FUNDS AND JA...
Více zde

ENTRADA THERAPEUTICS REPORTS POSITIVE PRELIMINARY DATA IN HEALTHY VOLUNTEERS FROM PHASE 1 ENTR-601-44-101 TRIAL FOR DUCHENNE MUSCULAR DYSTROPHY

24-06-2024
– ENTR-601-44 WAS WELL-TOLERATED IN HEALTHY VOLUNTEERS WITH NO SERIOUS ADVERSE EVENTS, NO DRUG-REL...
Více zde

ENTRADA THERAPEUTICS TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

03-06-2024
BOSTON, JUNE 03, 2024 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) IS A CLINICAL-ST...
Více zde

ENTRADA THERAPEUTICS TO PRESENT AT H.C. WAINWRIGHT 2ND ANNUAL BIOCONNECT INVESTOR CONFERENCE AT NASDAQ

16-05-2024
BOSTON, MAY 16, 2024 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) IS A CLINICAL-STA...
Více zde

ENTRADA THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

07-05-2024
– INITIATED DOSING OF THE FOURTH AND FINAL COHORT OF PHASE 1 CLINICAL TRIAL OF ENTR-601-44 FOR THE...
Více zde

ENTRADA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS

13-03-2024
– CASH RUNWAY EXTENDED THROUGH THE SECOND QUARTER OF 2026 – – $352 MILLION IN CASH, CASH EQUIV...
Více zde

ENTRADA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

07-02-2024
BOSTON, FEB. 07, 2024 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA), A CLINICAL-STAG...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-08 00:00:008-KStáhnout
2025-11-06 00:00:008-KStáhnout
2025-11-06 00:00:0010-QStáhnout
2025-08-06 01:00:008-KStáhnout
2025-08-06 01:00:0010-QStáhnout
2025-08-06 00:00:008-KStáhnout
2025-08-06 00:00:0010-QStáhnout
2025-06-11 01:00:008-KStáhnout
2025-06-11 00:00:008-KStáhnout
2025-06-03 01:00:008-KStáhnout
2025-06-03 00:00:008-KStáhnout
2025-05-08 01:00:008-KStáhnout
2025-05-08 01:00:0010-QStáhnout
2025-05-08 00:00:008-KStáhnout
2025-05-08 00:00:0010-QStáhnout
2025-04-29 01:00:008-KStáhnout
2025-04-29 00:00:008-KStáhnout
2025-03-24 00:00:008-KStáhnout
2025-03-23 23:00:008-KStáhnout
2025-02-27 00:00:008-KStáhnout
2025-02-27 00:00:0010-KStáhnout
2025-02-26 23:00:008-KStáhnout
2025-02-26 23:00:0010-KStáhnout
2025-02-24 00:00:008-KStáhnout
2025-02-23 23:00:008-KStáhnout
2025-02-03 00:00:008-KStáhnout
2025-02-02 23:00:008-KStáhnout
2025-01-15 00:00:008-KStáhnout
2025-01-14 23:00:008-KStáhnout
2024-11-05 00:00:008-KStáhnout
2024-11-05 00:00:0010-QStáhnout
2024-11-04 23:00:008-KStáhnout
2024-11-04 23:00:0010-QStáhnout
2024-08-13 01:00:008-KStáhnout
2024-08-13 01:00:0010-QStáhnout
2024-08-13 00:00:008-KStáhnout
2024-08-13 00:00:0010-QStáhnout
2024-06-24 01:00:008-KStáhnout
2024-06-24 00:00:008-KStáhnout
2024-06-13 01:00:008-KStáhnout
2024-06-13 00:00:008-KStáhnout
2024-05-07 01:00:008-KStáhnout
2024-05-07 01:00:0010-QStáhnout
2024-05-07 00:00:008-KStáhnout
2024-05-07 00:00:0010-QStáhnout
2024-03-13 00:00:008-KStáhnout
2024-03-13 00:00:0010-KStáhnout
2024-03-12 23:00:008-KStáhnout
2024-03-12 23:00:0010-KStáhnout
2024-01-03 00:00:008-KStáhnout
2024-01-02 23:00:008-KStáhnout
2023-12-06 00:00:008-KStáhnout
2023-12-05 23:00:008-KStáhnout
2023-11-22 00:00:008-KStáhnout
2023-11-21 23:00:008-KStáhnout
2023-11-07 00:00:008-KStáhnout
2023-11-07 00:00:0010-QStáhnout
2023-11-06 23:00:008-KStáhnout
2023-11-06 23:00:0010-QStáhnout
2023-11-01 00:00:008-KStáhnout
2023-10-31 23:00:008-KStáhnout
2023-09-29 01:00:008-KStáhnout
2023-09-29 00:00:008-KStáhnout
2023-09-21 01:00:008-KStáhnout
2023-09-21 00:00:008-KStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-08 01:00:008-KStáhnout
2023-08-08 01:00:0010-QStáhnout
2023-08-08 00:00:008-KStáhnout
2023-08-08 00:00:0010-QStáhnout
2023-08-01 01:00:008-KStáhnout
2023-08-01 00:00:008-KStáhnout
2023-06-08 01:00:008-KStáhnout
2023-06-08 00:00:008-KStáhnout
2023-05-10 01:00:008-KStáhnout
2023-05-10 01:00:0010-QStáhnout
2023-05-10 00:00:008-KStáhnout
2023-05-10 00:00:0010-QStáhnout
2023-04-04 01:00:008-KStáhnout
2023-04-04 00:00:008-KStáhnout
2023-03-06 00:00:008-KStáhnout
2023-03-06 00:00:0010-KStáhnout
2023-03-05 23:00:008-KStáhnout
2023-03-05 23:00:0010-KStáhnout
2023-02-09 00:00:008-KStáhnout
2023-02-08 23:00:008-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-12-19 00:00:008-KStáhnout
2022-12-18 23:00:008-KStáhnout
2022-12-08 00:00:008-KStáhnout
2022-12-07 23:00:008-KStáhnout
2022-11-07 00:00:008-KStáhnout
2022-11-07 00:00:0010-QStáhnout
2022-11-06 23:00:008-KStáhnout
2022-11-06 23:00:0010-QStáhnout
2022-08-11 01:00:008-KStáhnout
2022-08-11 01:00:0010-QStáhnout
2022-08-11 00:00:008-KStáhnout
2022-08-11 00:00:0010-QStáhnout
2022-06-03 01:00:008-KStáhnout
2022-06-03 00:00:008-KStáhnout
2022-05-12 01:00:008-KStáhnout
2022-05-12 01:00:0010-QStáhnout
2022-05-12 00:00:008-KStáhnout
2022-05-12 00:00:0010-QStáhnout
2022-03-22 00:00:008-KStáhnout
2022-03-21 23:00:008-KStáhnout
2022-03-15 00:00:008-KStáhnout
2022-03-15 00:00:0010-KStáhnout
2022-03-14 23:00:008-KStáhnout
2022-03-14 23:00:0010-KStáhnout
2021-12-09 00:00:008-KStáhnout
2021-12-09 00:00:0010-QStáhnout
2021-12-08 23:00:008-KStáhnout
2021-12-08 23:00:0010-QStáhnout
2021-11-02 00:00:008-KStáhnout
2021-11-01 23:00:008-KStáhnout
preloader